Dr Agarwals Health Care
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Dr. Agarwal's Health Care is poised for sustained growth, driven by aggressive expansion plans and a strong market position in the eye care sector. Management's commitment to opening 60 new facilities in FY27, particularly in high-demand regions like Delhi NCR and Mumbai, is expected to enhance revenue streams significantly. The company's focus on premium surgical procedures, such as Femto Cataracts, aligns with the projected 12-14% CAGR of the Indian eye care services market. Despite potential execution risks associated with rapid expansion and initial operating losses from new facilities, Vista's financial outlook remains stable, with revenue growth and margins expected to hold steady. The anticipated completion of the merger process and the commissioning of the new Chennai facility are key catalysts for future growth. However, challenges such as securing skilled ophthalmologists and managing technology upgrades could impact operational efficiency. Overall, the macroeconomic environment in India supports this growth trajectory, with favorable liquidity conditions and a robust demand for healthcare services. Over the next 12-24 months, the company must navigate these challenges while capitalizing on its strong brand equity and operational expertise to capture market share
Why We Like This Stock
- Aggressive expansion with plans to open 60 new facilities in FY27, enhancing market penetration
- Strong growth in premium surgical procedures aligns with the expanding Indian eye care market
- Stable financial outlook with consistent revenue growth and margins expected to remain stable
Things To Watch Out For
- Execution risks related to rapid expansion and initial operating losses from new facilities
- Potential staffing challenges due to a shortage of skilled ophthalmologists in India
- Increased capital expenditure requirements for continuous technology upgrades could impact profitability
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,332 | 1,711 | 2,080 | 2,349 | 2,803 |
| Profit Before Tax (Cr.) | 116 | 146 | 248 | 338 | 391 |
| PBT Margin | 8.7% | 8.5% | 1192.3% | 14.4% | 13.9% |
| Net Profit (Cr.) | 96 | 111 | 168 | 230 | 210 |
| Earnings Per Share | 2.6 | 2.7 | 4.2 | 5.7 | 6.6 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Jeffries | ▲ Buy | 600 | 05-Aug-2026 |
| Morgan Stanley | ▲ Overweight | 576 | 05-Aug-2026 |
| Motilal Oswal | ▲ Buy | 610 | 08-Jun-2026 |
Company Overview
Show Company Profile
Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the treatment of glaucoma and pterygium; doctor consultation services; and diagnostic services for eye disorders along with non-surgical treatments, including retinal laser therapy and dry eye treatment services. It also sells glasses, lenses, contact lenses, and frames; and eye care-related pharmaceutical products. The company was incorporated in 2010 and is based in Chennai, India.